Valuation: Edesa Biotech, Inc.

Market Cap 50.33M 44.26M 41.12M 37.82M 70.92M 4.87B 72.2M 492M 192M 2.38B 189M 185M 8.25B P/E 2026 *
-3.41x
P/E 2027 * -2.82x
Enterprise Value 50.33M 44.26M 41.12M 37.82M 70.92M 4.87B 72.2M 492M 192M 2.38B 189M 185M 8.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
81.34%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week-15.77%
Current month-30.38%
1 month-25.92%
3 months-16.52%
6 months+290.34%
Current year+298.59%
1 week 5.3
Extreme 5.3
6.6
1 month 5.3
Extreme 5.3
8.89
Current year 0.72
Extreme 0.72
20.32
1 year 0.72
Extreme 0.72
20.32
3 years 0.72
Extreme 0.72
20.32
5 years 0.72
Extreme 0.72
84
10 years 0.72
Extreme 0.72
133.7
Manager TitleAgeSince
Chief Executive Officer 55 2015-07-31
President 48 2019-06-06
Director of Finance/CFO 57 2025-04-30
Director TitleAgeSince
Chairman 50 2019-06-06
Director/Board Member 55 2023-05-22
Director/Board Member 60 2023-05-22
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Free

Founder

3,378 0.0380%
6/16/26 Free

Founder

153,550 1.7268%
6/16/26 Sell

Founder

153,530 1.7266%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-15.77%+137.82%-2.00% 50.51M
+1.23%+0.35%+51.62%+87.98% 55.27B
+5.09%+6.24%+63.15%+62.06% 54.15B
+0.72%-0.05%+3.84%+409.54% 23.11B
+0.25%+0.55%-19.67%-15.22% 23.22B
+1.03%-0.20%+36.49%-3.59% 20.33B
-0.37%+0.71%+31.36%-31.61% 17.91B
+0.87%-0.19%+39.07%+600.00% 15.76B
-2.54%-8.73%+164.11%+289.45% 15B
+1.22%-0.05%+22.58%+182.63% 13.82B
Average +0.71%-0.93%+53.04%+157.92% 23.86B
Weighted average by Cap. +1.56%+2.77%+44.44%+138.37%

Financials

2026 *2027 *
Net sales - -
Net income -14.54M -12.78M -11.88M -10.92M -20.49M -1.41B -20.85M -142M -55.4M -687M -54.57M -53.39M -2.38B -26.51M -23.32M -21.66M -19.92M -37.36M -2.57B -38.03M -259M -101M -1.25B -99.53M -97.38M -4.34B
Net Debt - -
Logo Edesa Biotech, Inc.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.
Employees
17
Date Price Change Volume
26-07-23 US$5.660 -0.35% 93,814
26-07-22 US$5.680 -5.80% 69,863
26-07-21 US$6.030 +3.61% 50,224
26-07-20 US$5.820 -11.82% 83,277
26-07-17 US$6.600 -1.79% 39,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
5.660USD
Average target price
16.33USD
Spread / Average Target
+188.57%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EDSA Stock